AI-Integrated Biotechnology Hub

• AI-integrated biotechnology hubs are coordinated platforms that merge multimodal biological data, AI reasoning, automation, and governance into a unified research ecosystem.
• They integrate lab-scale orchestration with campus-wide digital twins to enable efficient design-build-test-learn cycles, reducing exploration time and enhancing throughput.
• Robust data interoperability, embedded governance, and federated learning ensure these hubs overcome data bottlenecks and meet the regulatory demands of modern biotechnological research.

An AI-Integrated Biotechnology Hub is a coordinated platform in which biological data acquisition, knowledge representation, machine learning, experiment execution, digital simulation, and governance are organized as one system rather than as disconnected tools. Recent work instantiates the concept as a purpose-built research ecosystem uniting residential, commercial, clinical, and research facilities under a central, AI-driven operating system, as an AI-native FAIR and governance-aware decision layer for biomedical materials discovery, as a multi-agent operating system for human biology, and as a whole-lab orchestration layer for self-driving laboratories (Zhavoronkov et al., 24 Sep 2025, Mei et al., 20 May 2026, Wang et al., 27 Aug 2025, Fehlis et al., 1 Apr 2025). Across these formulations, the hub is defined less by any single algorithm than by the tight coupling of multimodal data, AI reasoning, automation, and translational control.

1. Conceptual basis

The immediate scientific motivation for the hub model is that biotechnology problems combine representations that are difficult to unify within purely data-driven pipelines. In automated biodesign, genetic parts, operons, pathways, host interactions, and design rules are naturally symbolic and relational, whereas system behavior is quantitative, dynamic, and noisy; the same system therefore requires logical structure and numerical prediction simultaneously (Dai et al., 2021). This is one reason recent work argues that mainstream machine learning, especially deep learning, is often poorly matched to synthetic biology when experiments are expensive, slow, and limited in number (Dai et al., 2021).

At the same time, the convergence of AI and synthetic biology has shifted attention from isolated predictive models to integrated design-build-test-learn workflows. LLMs, biological design tools, robotics, and automated analytics are described as enabling the automated design-build-test-learn cycles for engineered biological systems, while robotic subsystems already handle material transport, instrumentation control, colony picking, liquid handling, incubation, and chromatography (Vindman et al., 2024). A hub, in this sense, is not merely a computational service layer; it is an ecosystem in which design, execution, analysis, and revision are coupled.

A further driver is the data bottleneck. Biology now produces large data volumes, but the literature on interoperable biological data argues that progress remains slow and fragmented because standards, tooling, and cross-modal integration are insufficient for AI-scale modeling (Aevermann et al., 10 Oct 2025). This suggests that a biotechnology hub must be both a scientific architecture and an infrastructure architecture: it must integrate models and experiments, but also standards, metadata, storage, and access patterns.

2. Architectural organization

A recurrent architectural pattern is the layered pipeline. In the biotechnology-industry digital-twin framework, the stack is explicitly organized into an IoBNT layer, a CNN layer, a federated learning layer, and a digital-twin layer. Bio-nano devices gather image-based biological data, local CNNs perform machine vision, model updates are aggregated across three clients using Flower, and the resulting global model is used to build and refine digital twins of microorganisms such as bacteria (Mohammad et al., 2024). This architecture treats sensing, perception, distributed learning, and simulation as coordinated layers of one system.

At laboratory scale, orchestration platforms generalize the same logic to heterogeneous wet-lab environments. Artificial is described as a whole-lab orchestration and scheduling system whose front end includes Labs, Assistants, Workflows, LabOps, and a digital-twin visualization layer, while its backend exposes orchestration, scheduler/executor, and structured data records through a Lab API supporting GraphQL, gRPC, and REST (Fehlis et al., 1 Apr 2025). The architectural emphasis is not on a single instrument controller, but on a control plane that spans instruments, robots, informatics systems, AI services, and human operators.

At organismal scale, the architectural unit becomes the agent hierarchy. The Full-Body AI Agent is built around a supervisor agent plus seven biologically grounded basic agents—Molecule, Organelle, Cell, Tissue, Organ, Organ System, and Body System—communicating through standardized data exchange protocols (Wang et al., 27 Aug 2025). The central computational function is task decomposition and cross-scale result integration rather than monolithic inference.

A broader urban or campus-scale formulation extends the same pattern beyond the laboratory. The mixed-use AI-Integrated Biotechnology Hub proposed for biotechnology R&D is organized around advanced residential real estate, commercial amenities, biotechnology research facilities, a research hospital, and a central AI-based operating system. That operating system is described as three-tiered, with personal AI agents, facility-level AI agents, and a central AI reasoning and orchestration system (Zhavoronkov et al., 24 Sep 2025). The architectural consequence is that the hub can be instantiated as a lab platform, a digital-twin platform, a multi-agent biology system, or a physically embedded research ecosystem.

3. Data, knowledge representation, and interoperability

In most hub designs, knowledge infrastructure is a core component rather than an accessory. KG-Hub frames biological knowledge graphs as reusable computational infrastructure and provides a modular extract-transform-load pattern built from kghub-downloader, Koza, and KGX, with Biolink Model compliance, OBO ontology integration, monthly versioned builds, permanent URLs, and cloud-hosted browsable artifacts on AWS S3 and CloudFront (Caufield et al., 2023). Its significance lies in making biological knowledge graph construction reproducible, exchangeable, and directly usable for graph machine learning tasks such as node embeddings, link prediction, and node classification (Caufield et al., 2023).

The same requirement appears in multimodal biological data systems. The Full-Body AI Agent places a Data Commons and Common Format standards at the center of cross-scale biology, explicitly naming FASTA and PDB for molecular data, FHIR, JSON, XML, and Turtle for clinical data, DICOM for imaging, and H5AD and single-cell formats for cellular data (Wang et al., 27 Aug 2025). Work on AI-scale biological data similarly argues for federated rather than centralized architecture, separation of metadata from raw data, FAIR-by-design data release, and progressive standardization through formats such as croissant, OME-Zarr, AnnData, TileDB-SOMA, and modality-specific schemas (Aevermann et al., 10 Oct 2025). In both cases, interoperability is treated as a prerequisite for model training rather than a downstream curation exercise.

AIMBio-Mat makes this logic explicit in formal terms. It defines a typed knowledge graph

$\mathcal{G}=(\mathcal{V},\mathcal{E},\tau,\phi)$

and a full record

$$\mathcal{D}_i=\{\bm{x}_i,\bm{p}_i,\bm{s}_i,\bm{c}_i,\bm{y}_i,\bm{u}_i,\bm{g}_i,\bm{r}_i\},$$

so that the learning object contains composition, processing, structure, biological context, outcomes, uncertainty, governance metadata, and provenance links (Mei et al., 20 May 2026). The same paper also defines a record-level AI-readiness score,

$$Q_i=\alpha M_i+\beta U_i+\gamma P_i+\delta G_i+\zeta N_i,$$

where metadata completeness, uncertainty reporting, provenance depth, governance clarity, and negative/null results determine whether a record is fit for downstream modeling (Mei et al., 20 May 2026). This formalization reflects a core hub principle: biological data must remain auditable scientific records.

Domain-specific hubs instantiate the same design in narrower knowledge domains. The Potato Knowledge Hub combines a functional gene database containing 2,571 non-redundant literature-reported functional genes mapped to DMv8.1 with a retrieval-augmented knowledge base built from 3,233 curated high-quality papers. Its query pipeline uses SnowFlake embeddings, top-100 retrieval, reranking with bge-reranker-v2-m3, and answer generation from the top 10 chunks with Qwen3-235B-A22B, while preserving literature citations and sequence retrieval functions (Yuxin et al., 30 May 2025). This is a verticalized example of how a hub can link curation, harmonized identifiers, RAG, and interactive scientific assistance in one platform.

4. Closed-loop experimentation and laboratory autonomy

The laboratory function of the hub is most clearly expressed in design-build-test-learn systems. In abductive meta-interpretive learning for synthetic biology, the learning machine is intended to exploit domain knowledge, learn first-order logical hypotheses, optimize model structure and parameters jointly, and actively generate hypotheses and examples to reduce experimental cost and annotation effort (Dai et al., 2021). The framework is presented as a richer learning component inside DBTL, bridging “perception” and “reasoning” rather than performing simple regression on assay outputs (Dai et al., 2021).

Artificial turns this closed loop into a whole-lab operating model. Its self-driving cycle is organized as Design, Run, Optimize, and Learn, with LabOps using heuristics, constraints, and batching to allocate instruments, personnel, and other shared resources efficiently (Fehlis et al., 1 Apr 2025). In a proof-of-concept self-driving generative virtual screening workflow for SARS-CoV-2 main protease, BioNeMo NIM microservices were orchestrated iteratively until a binding affinity threshold of $-1.4$ million was met and at least ten molecules exceeded the required score threshold after three self-driving iterations (Fehlis et al., 1 Apr 2025). The central point is that AI models are treated as workflow components subject to criteria-based stopping and automated handoff to downstream steps.

AutoDNA extends laboratory autonomy further by co-designing models, procedures, and instruments. Its chemical planning module includes the Experiment Planner Agent, Hypothesis Proposer Agent, Literature Researcher Agent, and Reagent Manager Agent, while its hardware execution module includes the Program Developer Agent and the Hardware Executor & Validator Agent (Wu et al., 3 Jul 2025). Instrument capabilities are abstracted into AI-native atomic services, and the system can schedule concurrent multi-user requests, reroute to equivalent devices, and iteratively refine procedures without human intervention (Wu et al., 3 Jul 2025). In one multi-experiment scenario, HEVA reduced total exploration time from 1,434.7 min to 398.7 min, and the abstract reports a 3-fold throughput improvement in multi-user settings (Wu et al., 3 Jul 2025).

Closed-loop discovery is increasingly formalized as constrained optimization rather than heuristic trial management. AIMBio-Mat states the candidate-selection problem as

$$\bm{x}^{\ast} \in \arg\max_{\bm{x}\in\Omega} \; \bm{f}(\bm{x}) \quad \text{subject to} \quad g_k(\bm{x}) \leq 0,$$

and defines a cost- and safety-aware acquisition function

$$a_t(\bm{x}) = \mathrm{EHVI}_t(\bm{x};\bm{r}) \; P_t\!\left(\bigcap_{k=1}^{K}\{g_k(\bm{x}) \leq 0\}\right) \; \frac{S_t(\bm{x})}{C_t(\bm{x})+\epsilon}.$$

The intended effect is that the next experiment is chosen on the basis of expected Pareto improvement, feasibility, safety, and cost simultaneously (Mei et al., 20 May 2026). In this formulation, the hub does not simply automate experiments; it computes experiment value under uncertainty.

5. Multiscale modeling, digital twins, and biological agents

Digital representation is another defining feature of the hub. In biotechnology-industry digital twins, IoBNT devices, MobileNetV2-based local CNNs, federated learning across three clients, and virtual deployment are used to create and refine bacteria digital twins while preserving raw-data locality (Mohammad et al., 2024). The reported aim is improved reliability and safety of microorganism digital twins, maintained accuracy, reduced bandwidth usage, and collaborative learning across hospitals, laboratories, and other sites (Mohammad et al., 2024). The digital twin in this setting is both a model artifact and an operational layer for monitoring and simulation.

At larger biological scales, recent systems shift from single digital twins to coordinated multiscale agents. The Full-Body AI Agent defines its formal workflow as Data perception, Hypothesis generation, Task decomposition, Task execution by basic agents, and Result integration and iterative refinement, with bidirectional cross-scale reasoning between lower-level molecular or cellular findings and higher-level physiological constraints (Wang et al., 27 Aug 2025). Its two specialized implementations—the Metastasis AI Agent and the Drug AI Agent—show how molecular, cellular, tissue, organ, organ-system, and body-system constraints can be integrated into metastasis scoring and drug-development workflows (Wang et al., 27 Aug 2025).

AIDO generalizes the same ambition into a system of integrated multiscale foundation models. Its development stages are “Divide and conquer,” “Connect the dots,” and “Piece it all together,” linking modality-specific modules for molecules, networks, cells, and phenotypes through shared representations, 2D positional encodings, differentiable computation graphs, and hierarchical optimization (Song et al., 2024). In parallel, AI-driven multi-omics integration for causal genotype-environment-phenotype modeling proposes a central dogma-inspired end-to-end flow,

$$\text{DNA} \rightarrow \text{RNA} \rightarrow \text{protein} \rightarrow \text{metabolites} \rightarrow \text{phenotype},$$

combined with physics-informed, context-specific multi-scale knowledge graphs (Wu et al., 2024). These frameworks treat the hub as a computational substrate for cross-level causal reasoning rather than a repository of independent predictors.

Proteomics roadmaps extend the same trajectory toward AI-empowered virtual cells. The strategic priorities for AI and proteomics call for an AI-friendly ecosystem for data generation, sharing, and analysis, then for improvements in identification and quantification, protein complex characterization, spatial and perturbation proteomics, multi-omics integration, and finally AI-empowered virtual cells (Sun et al., 21 Feb 2025). A plausible implication is that multiscale digital twins, virtual cells, and full-body agents are not separate research lines, but adjacent formulations of the same hub objective: systemically consistent biological modeling from molecule to organism.

6. Governance, security, and accountability

The hub concept is inseparable from governance because the same integration that increases discovery speed also increases operational and societal risk. Work on the convergence of AI and synthetic biology emphasizes reliability, opacity, dual use, workforce deskilling, and the “pacing problem” in regulation, and recommends human-in-the-loop oversight, explainability, auditability, simulation sandboxes, open-access repositories, sequence screening and logging, and adaptive regulation (Vindman et al., 2024). The relevant claim is not simply that AI-biotech systems need ethics review, but that governance must be embedded into increasingly automated workflows.

Security is similarly operationalized rather than appended. MLSecOps in Biotechnology Industry 5.0 defines a dual mandate: use machine learning to protect biotechnology systems through anomaly detection, intrusion detection, ransomware detection, vulnerability identification, monitoring, and forecasting, while also securing the ML systems themselves against backdoors, malicious training samples, adversarial examples, drift, and compromised retraining or deployment pipelines (Pervez et al., 2024). In an AI-integrated hub, model supply chains, IoT devices, cloud resources, and biological data pipelines become part of one attack surface.

Some hub proposals therefore make governance a technical layer. AIMBio-Mat includes governance and user interaction as one of its five main layers, with role-based access, encryption, audit logs, de-identification or tokenization, consent and data-use records, and risk-tiered governance. It also states a sharp boundary: AIMBio-Mat is exploratory and preclinical discovery infrastructure, not clinical decision-support software, and any clinical or regulated-device use would require separate validation, change control, and regulatory review (Mei et al., 20 May 2026). The mixed-use R&D hub model likewise places dynamic consent, data trusts, and multi-stakeholder oversight at the center of its operating model, specifically to manage longitudinal multimodal data generated by residents, hospitals, and biotechnology facilities (Zhavoronkov et al., 24 Sep 2025).

Federated learning is often adopted as a practical privacy mechanism inside this governance architecture. In the biotechnology-industry digital-twin framework and the mixed-use AI-Integrated Biotechnology Hub, distributed clients can contribute model updates without exposing raw sensitive biological or personal data, thereby supporting collaborative intelligence while preserving data locality (Mohammad et al., 2024, Zhavoronkov et al., 24 Sep 2025). This suggests that privacy-preserving learning is not an optional feature but one of the main technical enablers of hub-scale coordination.

7. Representative implementations and developmental trajectory

The literature already contains multiple domain-specific implementations that illustrate how the hub concept is being specialized across biological subfields.

Platform	Domain	Integrative mechanism
KG-Hub (Caufield et al., 2023)	Biomedical knowledge graphs	Biolink-compliant ETL, OBO integration, graph ML
Artificial (Fehlis et al., 1 Apr 2025)	Drug discovery laboratories	whole-lab orchestration, LabOps, BioNeMo integration
AutoDNA (Wu et al., 3 Jul 2025)	Autonomous biomolecular engineering	model-instrument co-design, multi-user autonomous execution
Potato Knowledge Hub (Yuxin et al., 30 May 2025)	Potato functional genomics	curated gene database, RAG assistant, sequence retrieval
Bio AI Agent (Ni et al., 11 Nov 2025)	Autonomous CAR-T development	six-agent pipeline for target, toxicity, design, IP, and translation
BioImage.IO Chatbot (Lei et al., 2023)	Computational bioimaging	RAG, code execution, tool invocation, microscopy control
AI for Food (Datta et al., 25 Sep 2025)	Sustainable food innovation	ingredient-to-recipe closed-loop design–build–test–learn cycle

These implementations cover different biological substrates and operational scales. Bio AI Agent organizes autonomous CAR-T development through Target Selection, Toxicity Prediction, Molecular Design, Patent Intelligence, Clinical Translation, and Decision Orchestration agents, integrating a knowledge graph of more than 10,000 cancer-associated targets with GTEx, Human Protein Atlas, FAERS, EudraVigilance, patent databases, and regulatory guidance (Ni et al., 11 Nov 2025). AI for Food positions ingredient design, formulation development, fermentation and production, texture analysis, sensory properties, manufacturing, and recipe generation as one predictive, design-driven cycle (Datta et al., 25 Sep 2025). BioImage.IO Chatbot turns documentation, models, APIs, analysis code, and even microscopy control into a single conversational layer for integrative computational bioimaging (Lei et al., 2023).

The developmental trajectory remains uneven. Several frameworks are still at proof-of-concept or preclinical stages: abductive meta-interpretive learning for automated biodesign is demonstrated on synthetic data from a modified Weiße model for a three-gene operon (Dai et al., 2021); Bio AI Agent is largely retrospective and prototype-level; AIMBio-Mat explicitly limits itself to exploratory and preclinical discovery (Ni et al., 11 Nov 2025, Mei et al., 20 May 2026). Other papers identify persistent obstacles, including lack of standardization, scarce multimodal data, cultural and nutritional diversity, transferability and scalability, and dependence on background knowledge or curated action spaces (Datta et al., 25 Sep 2025, Dai et al., 2021). Even so, the collective direction is consistent: the hub is emerging as a unifying form in which interoperable data, multiscale models, laboratory autonomy, and governance-aware decision systems are assembled into a common biotechnology infrastructure.